natgillin/translations-raw huggingface dataset:
Other: dual blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomised, controlled trials (ONTARGET [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and VA NEPHRON-D [The Veterans Affairs Nephropathy in Diabetes]) have examined the use of the combination of an ACE inhibitor with an angiotensin II receptor blocker (ARB). 
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) i VA NEPHRON-D (eng. The Veterans Affairs Nephropathy in Diabetes)) ispitivala su primjenu kombinacije ACE inhibitora s blokatorima angiotenzin II receptora (ARB-ovima).
Amlodipine dosage recommendations have not been established in patients with mild to moderate hepatic impairment. 
Preporučeno doziranje amlodipina nije ustanovljeno u bolesnika s blagim do umjerenim oštećenjem jetre.
Similar changes were found in the valsartan alone group (exposure 8.5-11.0 times the clinical dose of 160 mg valsartan). 
Slične su promjene nađene i u skupini koja je bila samo na valsartanu (izloženost 8,511,0 puta viša od izloženosti kliničkom dozom od 160 mg valsartana).
When switching eligible hypertensive patients (see section 4.1) with hepatic impairment to amlodipine or amlodipine/valsartan, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used. 
Prilikom prebacivanja hipertenzivnih bolesnika koji ispunjavaju uvjete za liječenje (vidjeti dio 4.1) s oštećenjem jetre na amlodipin ili amlodipin/valsartan, treba se koristiti najniža dostupna doza amlodipina u monoterapiji ili amlodipina kao komponente.
Particular caution should be exercised when administering amlodipine/valsartan to patients with mild to moderate hepatic impairment or biliary obstructive disorders. 
Nužan je poseban oprez kod primjene amlodipina/valsartana bolesnicima s blagim do umjerenim oštećenjem jetre ili opstruktivnim poremećajima žučnog sustava.
Candesartan 32 * These limits are not applicable for batches where more than one of the above N-nitrosamines has been identified simultaneously; such batches should be rejected. 
valsartan 320 losartan 150 olmesartan 40 irbesartan 300 kandesarta n * Te granične vrijednosti nisu primjenjive za serije gdje je utvrđeno istodobno postojanje više od jednog od prethodno navedenih N-nitrozamina; takve serije treba odbaciti.
Very rare (may affect up to 1 in 10,000 people): Decreased number of white blood cells, decrease in blood platelets which may result in unusual bruising or easy bleeding (red blood cell damage); excess sugar in blood (hyperglycaemia); swelling of the gums, abdominal bloating (gastritis); abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests; increased muscle tension; inflammation of blood vessels often with skin rash, sensitivity to light; 
Vrlo rijetko (mogu se javiti u do 1 na 10 000 osoba): Smanjen broj bijelih krvnih stanica, smanjen broj krvnih pločica što može rezultirati stvaranjem neuobičajenih modrica ili lakog krvarenja (oštećenje crvenih krvnih stanica); povišen šećer u krvi (hiperglikemija), oticanje desni, nadutost u trbuhu (gastritis), nepravilna jetrena funkcija, upala jetre (hepatitis), žutilo kože (žutica), povišeni jetreni enzimi što može imati učinak na neke medicinske testove, povećana napetost mišića, upala krvnih žila često s kožnim osipom, osjetljivost na svjetlost.
You can take Amlodipine/Valsartan Mylan with or without food. 
Amlodipin/Valsartan Mylan možete uzimati s hranom ili bez nje.
The effect of amlodipine/valsartan on infants is unknown. 
Učinak amlodipina na dojenčad nije poznat.
Posology The recommended dose of Amlodipine/Valsartan Mylan is one tablet per day. 
Preporučena doza lijeka Amlodipin/Valsartan Mylan je jedna tableta na dan.
A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on amlodipine 10 mg in 78 % of patients treated with amlodipine/valsartan 10 mg/160 mg, compared to 67 % of patients remaining on amlodipine 10 mg. 
Multicentrično, randomizirano, dvostruko slijepo, aktivno kontrolirano ispitivanje paralelnih skupina je u bolesnika, koji nisu bili odgovarajuće kontrolirani amlodipinom 10 mg, pokazalo normalizaciju krvnog tlaka (donja vrijednost dijastoličkog krvnog tlaka u sjedećem položaju <90 mmHg na kraju ispitivanja) u 78% bolesnika liječenih amlodipinom/valsartanom 10 mg/160 mg, u usporedbi s 67% bolesnika koji su ostali na amlodipinu 10 mg.
Common (may affect up to 1 in 10 people): Influenza (flu); blocked nose, sore throat and discomfort when swallowing; headache; swelling of arms, hands, legs, ankles or feet; tiredness; asthenia (weakness); redness and warm feeling of the face and/or neck. 
Česte (mogu se javiti u do 1 na 10 osoba): Influenca (gripa); začepljen nos, grlobolja i osjećaj nelagode pri gutanju; glavobolja; oticanje ruku, šaka, nogu, gležnjeva ili stopala; umor; astenija (slabost); crvenilo i osjećaj topline u licu i/ili vratu.
Hypromellose Titanium dioxide (E171) Macrogol 8000 
Ovojnica: hipromeloza titanijev dioksid (E171) makrogol 8000 talk žuti željezov oksid (E172)
Active-controlled trials in patients who were non-responders to monotherapy A multicentre, randomised, double-blind, active-controlled, parallel-group trial showed normalisation of blood pressure (trough sitting diastolic blood pressure <90 mmHg at the end of the trial) in patients not adequately controlled on valsartan 160 mg in 75 % of patients treated with amlodipine/valsartan 10 mg/160 mg and 62 % of patients treated with amlodipine/valsartan 5 mg/160 mg, compared to 53 % of patients remaining on valsartan 160 mg. 
Multicentrično, randomizirano, dvostruko slijepo, aktivno kontrolirano ispitivanje paralelnih skupina je u bolesnika, koji nisu bili odgovarajuće kontrolirani valsartanom 160 mg, pokazalo normalizaciju krvnog tlaka (donja vrijednost dijastoličkog krvnog tlaka u sjedećem položaju <90 mmHg na kraju ispitivanja) u 75% bolesnika liječenih amlodipinom/valsartanom 10 mg/160 mg i 62% bolesnika liječenih amlodipinom/valsartanom 5 mg/160 mg, u usporedbi s 53% bolesnika koji su ostali na valsartanu 160 mg.
Uncommon (may affect up to 1 in 100 people): Mood changes, anxiety, depression, sleeplessness, trembling, taste abnormalities, fainting, loss of pain sensation; visual disturbances, visual impairment, ringing in the ears; low blood pressure; sneezing/runny nose caused by inflammation of the lining of the nose (rhinitis); indigestion, vomiting (being sick); hair loss, increased sweating, itchy skin, skin discolouration; disorder in passing urine, increased need to urinate at night, increased number of times of passing urine; inability to obtain an erection, discomfort or enlargement of the breasts in men, pain, feeling unwell, muscle pain, muscle cramps; weight increase or decrease. 
Manje često (mogu se javiti u do 1 na 100 osoba): Promjene raspoloženja, tjeskoba, depresija, pospanost, drhtanje, poremećaji okusa, nesvjestica, gubitak osjećaja boli; poremećaji vida, oštećenje vida, zvonjava u ušima; niski krvni tlak; kihanje/curenje iz nosa uzrokovano upalom sluznice nosa (rinitis); loša probava, povraćanje; ispadanje kose, pojačano znojenje, svrbljiva koža, promjena boje kože; poremećaj mokrenja, pojačana potreba za mokrenjem noću, povećan broj mokrenja, nemogućnost postizanja erekcije, nelagoda ili povećanje dojki u muškaraca, bol, loše osjećanje, bol u mišićima, grčevi u mišićima; povećanje ili smanjenje tjelesne težine.
Rare (may affect up to 1 in 1,000 people): Feeling anxious; ringing in the ears (tinnitus); fainting; passing more urine than normal or feeling more of an urge to pass urine; inability to get or maintain an erection; sensation of heaviness; low blood pressure with symptoms such as dizziness, lightheadedness; excessive sweating; skin rash all over your body; itching; muscle spasm. 
Rijetke (mogu se javiti u do 1 na 1000 osoba): Osjećaj tjeskobe; zvonjava u ušima (tinitus); nesvjestica; pojačano mokrenje ili pojačan nagon na mokrenje; nemogućnost postizanja ili održavanja erekcije; osjećaj težine; niski krvni tlak sa simptomima poput omaglice, omamljenosti; pojačanog znojenja; kožni osip po čitavom tijelu; svrbež; grč mišića.
Consult a doctor immediately if you experience any of the following very rare, severe side effects after taking this medicine: 
Odmah se javite liječniku ako osjetite bilo koju od sljedećih vrlo rijetkih, teških nuspojava nakon uzimanja ovog lijeka: - Iznenadno piskanje pri disanju, bol u prsima, nedostatak zraka ili otežano disanje.
Your doctor may also check your kidney function; anticonvulsant agents (e.g. carbamazepine, phenobarbital, phenytoin, fosphenytoin, primidone); St. John's wort; nitroglycerin and other nitrates, or other substances called “vasodilators”; 
Liječnik će Vam možda provjeriti i bubrežnu funkciju; antikonvulzivni lijekovi (npr. karbamazepin, fenobarbital, fenitoin, fosfenitoin, primidon);
How to take Amlodipine/Valsartan Mylan 
Kako uzimati Amlodipin/Valsartan Mylan
The other ingredients are cellulose microcrystalline; crospovidone; magnesium stearate; silica colloidal anhydrous; hypromellose; macrogol 8000; talc, titanium dioxide (E171); iron oxide yellow (E172). 
Drugi sastojci su mikrokristalična celuloza, krospovidon, magnezijev stearat, koloidni bezvodni silicijev dioksid, hipromeloza, makrogol 8000, talk, titanijev dioksid (E171), žuti željezov oksid (E172).
The other ingredients are cellulose microcrystalline; crospovidone; magnesium stearate; silica colloidal anhydrous; hypromellose; macrogol 8000; talc; titanium dioxide (E171); iron oxide yellow (E172); iron oxide red (E172); iron oxide black (E172). 
Drugi sastojci su mikrokristalična celuloza, krospovidon, magnezijev stearat, koloidni bezvodni silicijev dioksid, hipromeloza, makrogol 8000, talk, titanijev dioksid (E171), žuti željezov oksid (E172), crveni željezov oksid (E172), crni željezov oksid (E172).
Uncommon (may affect up to 1 in 100 people): Dizziness; nausea and abdominal pain; dry mouth; drowsiness, tingling or numbness of the hands or feet; vertigo; fast heart beat including palpitations; dizziness on standing up; cough; diarrhoea; constipation; skin rash, redness of the skin; joint swelling, back pain; pain in joints. 
Manje česte (mogu se javiti u do 1 na 100 osoba): Omaglica; mučnina i bol u trbuhu; suha usta; omamljenost, trnci ili obamrlost šaka ili stopala; vrtoglavica; ubrzani otkucaji srca, uključujući osjećaj lupanja srca; omaglica kod ustajanja; kašalj; proljev; zatvor; kožni osip, crvenilo kože; oticanje zglobova, bol u leđima; bol u zglobovima.
Renal impairment There are no available clinical data in severely renally impaired patients. 
Oštećenje bubrega Klinički podaci u bolesnika s teškim oštećenjem bubrega nisu dostupni.
NDEA Limit in ppm in API 
NDMA Granična vrijednost u aktivnim farmaceutski m sastojcima (ppm)
Iron oxide yellow (E172) Iron oxide red (E172) Iron oxide black (E172) 
Ovojnica: hipromeloza titanijev dioksid (E171) makrogol 8000 talk žuti željezov oksid (E172) crveni željezov oksid (E172) crni željezov oksid (E172)
amlodipine/valsartan mylan 5 mg/80 mg 
amlodipin/valsartan mylan 5 mg/80 mg
Amlodipine/valsartan should be discontinued immediately in patients who develop angioedema and should not be re-administered. 
Bolesnici u kojih se razvije angioedem trebaju odmah prekinuti primjenu amlodipina/valsartana i više ga ne smiju ponovo uzimati.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg alone or with Amlodipine/Valsartan Mylan 5 mg/160 mg. 
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg može se primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 10 mg ili valsartanom 160 mg ili lijekom Amlodipin/Valsartan Mylan 5 mg/160 mg.
Extrapyramidal disorder 
Ekstrapiramidalni poremećaj
Each tablet contains 5 mg amlodipine (as amlodipine besilate) and 80 mg valsartan. 
Jedna tableta sadrži 5 mg amlodipina (u obliku amlodipinbesilata) i 80 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/80 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg alone. 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/80 mg se može primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 80 mg.
amlodipine/valsartan Mylan 10 mg/160 mg 
amlodipin/valsartan mylan 10 mg/160 mg
How to store Amlodipine/Valsartan Mylan 
Kako čuvati Amlodipin/Valsartan Mylan
amlodipine/valsartan mylan 5 mg/160 mg 
amlodipin/valsartan mylan 5 mg/160 mg
Other medicines and Amlodipine/Valsartan Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Common (may affect up to 1 in 10 people): Dizziness, sleepiness; palpitations (awareness of your heart beat); flushing, ankle swelling (oedema); abdominal pain, feeling sick (nausea). 
Često (mogu se javiti u do 1 na 10 osoba): Omaglica, pospanost; palpitacije (svijest o radu Vašeg srca); crvenilo uz osjećaj vrućine, oticanje gležnjeva (edem); bol u trbuhu, mučnina.
Each tablet contains 10 mg amlodipine (as amlodipine besilate) and 160 mg valsartan. 
Jedna tableta sadrži 10 mg amlodipina (u obliku amlodipinbesilata) i 160 mg valsartana.
Fertility There are no clinical studies on fertility with amlodipine/valsartan. 
Ne postoje klinička ispitivanja djelovanja amlodipina/valsartana na plodnost.
Amlodipine Common 
Amlodipin Često
Each tablet contains 5 mg amlodipine (as amlodipine besilate) and 160 mg valsartan. 
Jedna tableta sadrži 5 mg amlodipina (u obliku amlodipinbesilata) i 160 mg valsartana.
If you think you may be allergic, talk to your doctor before taking Amlodipine/Valsartan Mylan. 
Ako mislite da biste mogli biti alergični, porazgovarajte sa svojim liječnikom prije uzimanja lijeka Amlodipin/Valsartan Mylan. ako imate teške probleme s jetrom ili probleme sa žuči, poput bilijarne ciroze ili kolestaze.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg may be administered in patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg alone. 
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg može se primjenjivati u bolesnika čiji krvni tlak nije odgovarajuće kontroliran samo amlodipinom 5 mg ili valsartanom 160 mg.
ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE inhibitor or an angiotensin II receptor blocker (ARB) in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. 
ALTITUDE (eng. Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) je bilo ispitivanje osmišljeno za testiranje koristi dodavanja aliskirena standardnoj terapiji s
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg tablets are light brown, oval, biconvex film-coated tablet marked with “AV3” on one side and “M” on the other side. 
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg tablete su svjetlosmeđe, ovalne, bikonveksne filmom obložene tablete s oznakom „AV3“ na jednoj strani i „M“ na drugoj strani.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg tablets are yellow, oval, biconvex film-coated tablet marked with “AV2” on one side and “M” on the other side. 
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Amlodipin/Valsartan Mylan 5 mg/160 mg tablete su žute, ovalne, bikonveksne filmom obložene tablete s oznakom „AV2“ na jednoj strani i „M“ na drugoj strani.
Cardiac disorders 
Poremećaj koordiancije
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Light yellow, round, approximately 9 mm diameter, biconvex film-coated tablet debossed with “AV1” on one side and “M” on the other side. 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Svjetložuta, okrugla, bikonveksna filmom obložena tableta promjera približno 9 mm s utisnutom oznakom „AV1“ na jednoj strani i „M“ na drugoj strani.
No dosage adjustment of amlodipine/valsartan is required for patients with mild to moderate renal impairment (GFR >30 ml/min/1.73 m2). 
U bolesnika s blagim do umjerenim oštećenjem bubrega (GFR >30 ml/min/1,73 m2) doziranje amlodipina/valsartana nije potrebno prilagođavati.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Each tablet contains 5 mg amlodipine and 80 mg valsartan. 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Jedna tableta sadrži 5 mg amlodipina i 80 mg valsartana.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Each film-coated tablet contains 10 mg of amlodipine (as amlodipine besilate) and 160 mg of valsartan. 
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 10 mg amlodipina (u obliku amlodipinbesilata) i 160 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Each tablet contains 5 mg amlodipine and 160 mg valsartan. 
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Jedna tableta sadrži 5 mg amlodipina i 160 mg valsartana.
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Light brown, oval, approximately 15.6 mm × 7.8 mm, biconvex film-coated tablet debossed with “AV3” on one side and “M” on the other side. 
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete Svjetlosmeđa, ovalna, bikonveksna filmom obložena tableta dimenzija približno 15,6 mm × 7,8 mm s utisnutom oznakom „AV3“ na jednoj strani i „M“ na drugoj strani.
Vasculitis 
Vaskulitis
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets amlodipine/valsartan 
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete amlodipin/valsartan
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Yellow, oval, approximately 15.6 mm × 7.8 mm, biconvex film-coated tablet debossed with “AV2” on one side and “M” on the other side. 
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Žuta, ovalna, bikonveksna filmom obložena tableta dimenzija približno 15,6 mm × 7,8 mm s utisnutom oznakom „AV2“ na jednoj strani i „M“ na drugoj strani.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besilate) and 80 mg of valsartan. 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 5 mg amlodipina (u obliku amlodipinbesilata) i 80 mg valsartana.
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets amlodipine/valsartan 
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete amlodipin/valsartan
Amlodipine/Valsartan Mylan with food and drink Grapefruit and grapefruit juice should not be consumed by people who are taking Amlodipine/Valsartan Mylan. 
Bolesnici koji uzimaju Amlodipin/Valsartan Mylan ne smiju konzumirati grejp ili sok od grejpa.
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets amlodipine/valsartan 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete amlodipin/valsartan
Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Each film-coated tablet contains 5 mg of amlodipine (as amlodipine besilate) and 160 mg of valsartan. 
Amlodipin/Valsartan Mylan 5 mg/160 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 5 mg amlodipina (u obliku amlodipinbesilata) i 160 mg valsartana.
Rash 
Litij
Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets Tablet core: 
Amlodipin/Valsartan Mylan 10 mg/160 mg filmom obložene tablete
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Tablet core: 
Amlodipin/Valsartan Mylan 5 mg/80 mg filmom obložene tablete
if you are taking any of the following medicines used to treat high blood pressure: 
Nemojte više nikad uzimati Amlodipin/Valsartan Mylan. ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka:
Diarrhoea 
Takrolimus
Mylan Hrvatska d.o.o. 
Mylan Hungary Kft.
2 bottles with dosing syringe 
2 bočice štrcaljkom za doziranje
8.4 g 1 pre-filled syringe 
8.4 g 1 napunjena štrcaljka
8.4 g 7 pre-filled syringes 
8.4 g 7 napunjeni h štrcaljki
8.4 g 14 prefilled syringes 
8.4 g 14 napunjeni h štrcaljki štrcaljkom za doziranje
Your doctor will test for these changes. 
Vaš liječnik će provjeriti ove promjene.
Then go on with the regular schedule as prescribed. 
Zatim nastavite prema redovitom rasporedu, kako je propisano.
Week 2 onwards: • Continue with the standard dose. 
2. tjedan pa nadalje: • Nastavite uzimati standardnu dozu.
Such changes may in part be linked to disease control and lifestyle. 
Te promjene mogu biti djelomično povezane s kontrolom bolesti i stilom života.
Inform your doctor if you are pregnant or planning to become pregnant. 
Recite liječniku ako ste trudni ili planirate trudnoću.
Use with caution. 
Primjenjivati uz oprez.
Do not drive or operate machines if you experience these symptoms. 
Nemojte voziti ni raditi na stroju ako osjetite te simptome.
In some patients additional factor VIII was given. 
Neki bolesnici dodatno su primili faktor VIII.
What Invirase is and what it is used for 
Što je Invirase i za što se koristi
Age Group (Years) 
Dobna skupina (godine)
For these reasons it is very important to inform your doctor of any change in your condition. 
Stoga je vrlo važno da liječnika obavijestite o svim promjenama svog stanja.
If indicated, prevention of further absorption can be considered. 
Ako je indicirano, može se razmotriti prevencija daljnje apsorpcije.
A similar interaction with astemizole is likely. 
Vjerojatna je slična interakcija s astemizolom.
This medicine should be taken during pregnancy only after consultation with your doctor. 
Ovaj lijek se u trudnoći smije uzimati samo nakon savjetovanja s liječnikom.
An interaction is possible. 
Interakcija je moguća.
Your doctor may wish to do an ECG to check your heart beat. 
Liječnik će možda htjeti napraviti EKG da provjeri Vaše otkucaje srca.
Results of the “Low Age Group” are not shown as data are limited due to the small size of the group. 
Rezultati za „mlađu dobnu skupinu“ nisu prikazani jer su podaci ograničeni uslijed male veličine skupine.
Week 1: 
1. tjedan:
Marcelin et al (2007) 
Marcelin i sur. (2007)
Continue to take this medicine until your doctor tells you otherwise. 
Nastavite uzimati ovaj lijek sve dok Vam liječnik ne kaže drugačije.
Any of these other medicines: 
Bilo koji od sljedećih lijekova:
Should this happen to you, seek immediate advice from your doctor. 
Dogodi li se to Vama, odmah potražite savjet liječnika.
If you forget to take one dose, take this dose as soon as you remember together with some food. 
Zaboravite li uzeti jednu dozu, uzmite je čim se sjetite, s hranom.
What Invirase contains 
Što Invirase sadrži